Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTX-GRT7039 in Osteoarthritis Knee Pain
2024-515709-24-00Phase 3Completed
- Sponsor
- Grünenthal GmbH
- Start
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of RTX-GRT7039 in knee osteoarthritis (OA) and knee arthralgia, sponsored by Grünenthal GmbH. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs). Started Nov 2024; status: completed.
02
Drugs
RTX-GRT7039
03
Conditions
knee osteoarthritis (OA)knee arthralgia
Beyond the preview
Go deeper on 2024-515709-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515709-24-00.